CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants

Andrew D Redd; Alessandra Nardin; Hassen Kared; Evan M Bloch; Andrew Pekosz; Oliver Laeyendecker; Brian Abel; Michael Fehlings; Thomas C Quinn; Aaron Ar Tobian

doi:10.1101/2021.02.11.21251585

CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants

medRxiv [Preprint]. 2021 Feb 12:2021.02.11.21251585. doi: 10.1101/2021.02.11.21251585.

Authors

Andrew D Redd^{1

2}, Alessandra Nardin³, Hassen Kared³, Evan M Bloch⁴, Andrew Pekosz⁵, Oliver Laeyendecker^{1

2}, Brian Abel³, Michael Fehlings³, Thomas C Quinn^{1

2}, Aaron Ar Tobian⁴

Affiliations

¹ Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
² Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ ImmunoScape Pte Ltd, Singapore.
⁴ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁵ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Abstract

This study examined whether CD8+ T-cell responses from COVID-19 convalescent individuals(n=30) potentially maintain recognition of the major SARS-CoV-2 variants. Out of 45 mutations assessed, only one from the B.1.351 Spike overlapped with a low-prevalence CD8+ epitope, suggesting that virtually all anti-SARS-CoV-2 CD8+ T-cell responses should recognize these newly described variants.

Publication types

Preprint

Abstract

Publication types

Grants and funding